Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04389645|
Recruitment Status : Completed
First Posted : May 15, 2020
Last Update Posted : May 15, 2020
The proposed project will pilot incorporation of rapid serial measurements of IP-10 into a CDS tool for moderate and severe COVID-19 patients.
The tool was applied to all comers with confirmed COVID-19 diagnosis at a secondary medical center in Israel.
|Condition or disease||Intervention/treatment|
|COVID-19||Diagnostic Test: IP-10 in CDS protocol|
|Study Type :||Observational|
|Actual Enrollment :||52 participants|
|Official Title:||Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients|
|Actual Study Start Date :||April 7, 2020|
|Actual Primary Completion Date :||May 12, 2020|
|Actual Study Completion Date :||May 12, 2020|
- Diagnostic Test: IP-10 in CDS protocol
Dynamic IP-10 measurements in hospitalized COVID-19 positive patients
- IP-10 levels [ Time Frame: up to 24 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04389645
|Rabin Medical Center|
|Petach Tikva, Israel|
|Principal Investigator:||Shaul Lev, MD||Rabin Medical Center|